Previous 10 | Next 10 |
Amid the biotech bear market, there are companies that are trading on a deep bargain, yet you should be extremely careful before averaging down. Though I noticed the fundamental changes in Galapagos, I gave the company a year to turn around. Here, I presented to you three differen...
David Einhorn's 13F stock portfolio value decreased from $1.75B to $1.57B this quarter. Greenlight increased Chemours, Warner Bros. Discovery, Resideo, LivaNova, Kyndryl, and PLBY while dropping Jack in the Box and EchoStar. They also added Southwestern Energy, Weatherford plc, Intern...
The following slide deck was published by Galapagos NV in conjunction with their 2022 Q1 earnings call. For further details see: Galapagos NV 2022 Q1 - Results - Earnings Call Presentation
Galapagos NV (GLPG) Q1 2022 Results Conference Call May 6, 2022 08:00 AM ET Company Participants Sofie Van Gijsel - Senior Director, Investor Relations Paul Stoffels - Chief Executive Officer Bart Filius - Chief Operating Officer & Chief Financial Officer Walid Abi-Saab - Chief Medical Of...
Galapagos press release (NASDAQ:GLPG): Q1 GAAP EPS of -€0.20. Revenue of €136.3M (+19.7% Y/Y). "For 2022, we anticipate a significantly lower cash burn compared to 2021 of €450M-€490M, including anticipated net sales for Jyseleca between €65M-€75...
First three months 202 2 financial results : Jyseleca ® net sales reached € 14.4 million Group revenues + 20 % to € 136.3 million Operating loss -58 % to ...
M echelen, Belgium; 26 April 202 2 , 22 . 01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces that the proposed resolutions presented at the e xtraordinary and a nnual shareholdersȁ...
The Japanese Ministry of Health, Labour and Welfare (MHLW) approved Gilead Sciences (NASDAQ:GILD), Galapagos (NASDAQ:GLPG) and Eisai's (OTCPK:ESALF) drug Jyseleca (filgotinib) to treat patients with moderate-to-severe active ulcerative colitis (UC), an inflammatory bowel diseas...
Ap proval of additional indication based on Phase 2b/3 SELECTION study in patients with moderate-to-severe ulcerative colitis Mechelen, Belgium; 28 March 2022, 0 8 . 01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) reports th...
-- Proposal of one-tier board structure & appointment of three new directors -- Mechelen, Belgium; 24 March 2022, 2 1 .01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for th...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...